These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate. Perez-Franco JE; Cruz-Barrera ML; Robayo ML; Lopez MC; Daza CD; Bedoya A; Mariño ML; Saavedra CH; Echeverry MC PLoS Negl Trop Dis; 2016 May; 10(5):e0004739. PubMed ID: 27243811 [TBL] [Abstract][Full Text] [Related]
10. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536 [TBL] [Abstract][Full Text] [Related]
11. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Kedzierski L; Sakthianandeswaren A; Curtis JM; Andrews PC; Junk PC; Kedzierska K Curr Med Chem; 2009; 16(5):599-614. PubMed ID: 19199925 [TBL] [Abstract][Full Text] [Related]
12. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance. Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568 [TBL] [Abstract][Full Text] [Related]
13. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate. Vouldoukis I; Rougier S; Dugas B; Pino P; Mazier D; Woehrlé F Vet Parasitol; 2006 Jan; 135(2):137-46. PubMed ID: 16242844 [TBL] [Abstract][Full Text] [Related]
14. Combined effect of the essential oil from Chenopodium ambrosioides and antileishmanial drugs on promastigotes of Leishmania amazonensis. Monzote L; Montalvo AM; Scull R; Miranda M; Abreu J Rev Inst Med Trop Sao Paulo; 2007; 49(4):257-60. PubMed ID: 17823757 [TBL] [Abstract][Full Text] [Related]
15. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect. Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133 [TBL] [Abstract][Full Text] [Related]
16. Effects of antimonial therapy for canine leishmaniasis on antibody titer. Amusategui I; Sainz A; Tesouro MA Ann N Y Acad Sci; 1998 Jun; 849():444-6. PubMed ID: 9668509 [No Abstract] [Full Text] [Related]
17. [Current situation and future of antileishmanial therapy in Colombia]. Soto J; Soto P Biomedica; 2006 Oct; 26 Suppl 1():194-206. PubMed ID: 17361855 [TBL] [Abstract][Full Text] [Related]
18. New delivery strategies for the old pentavalent antimonial drugs. Frézard F; Demicheli C Expert Opin Drug Deliv; 2010 Dec; 7(12):1343-58. PubMed ID: 21029028 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of leishmaniasis in India. Thakur CP Indian J Pediatr; 1987; 54(1):7-10. PubMed ID: 3030933 [No Abstract] [Full Text] [Related]
20. Application of nanotechnology in treatment of leishmaniasis: A Review. Akbari M; Oryan A; Hatam G Acta Trop; 2017 Aug; 172():86-90. PubMed ID: 28460833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]